Allergic contact dermatitis caused by methylphenidate

Contact Dermatitis

Volumn 65, Issue 3, 2011, Pages 183-185

  Vashi, Neelam A ^a   Souza, Aieska ^a   Cohen, Niki ^a   Franklin, Brielle ^a   Cohen, David E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

allergic contact dermatitis; methylphenidate; patch test

Indexed keywords

ACRYLIC ACID BUTYL ESTER; ACRYLIC ACID ETHYL ESTER; AMPHETAMINE; DEXAMPHETAMINE; METHACRYLIC ACID METHYL ESTER; METHYLPHENIDATE; PHTHALIC ACID DIBUTYL ESTER; PHTHALIC ACID DIOCTYL ESTER; SALICYLIC ACID PHENYL ESTER; TRICRESYL PHOSPHATE;

ANAMNESIS; ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD; FEMALE; HISTOPATHOLOGY; HUMAN; OUTCOME ASSESSMENT; PATCH TEST; PRURITUS; SCHOOL CHILD; SKIN ALLERGY; SKIN BIOPSY; SKIN BURNING SENSATION; SKIN EXAMINATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DERMATITIS, ALLERGIC CONTACT; DESONIDE; FEMALE; HUMANS; METHYLPHENIDATE; PATCH TESTS;

EID: 80051682415     PISSN: 01051873     EISSN: 16000536     Source Type: Journal    
DOI: 10.1111/j.1600-0536.2011.01949.x     Document Type: Article

References (10)

1. Ale I, Lachapelle J M, Maibach H I., Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther 2009: 26: 920-935.
2. Kalia Y N, Guy R H., Modeling transdermal drug release. Adv Drug Deliv Rev 2001: 48: 159-172. (Pubitemid 32434401)
3. Ball A M, Smith K M., Optimizing transdermal drug therapy. Am J Health Syst Pharm 2008: 65: 1337-1346.
4. Warshaw E M, Paller A S, Fowler J F, Zirwas M J., Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Clin Ther 2008: 30: 326-337. (Pubitemid 351479209)
5. Daytrana [Package Insert]: Wayne, PA, Shire US Inc., 2008.
6. Fowler J F, Warshaw E M, Squires L., Methylphenidate patch-test protocol and irritancy threshold determination in healthy adult subjects. Dermatitis 2009: 20: 271-274.
7. Shire Pharmaceuticals-Noven's DOT Matrix Technology: Shire US Inc., 2010. Available at: (last accessed 17 July 2010).
8. Williams A C., Transdermal and Topical Drug Delivery: From Theory to Clinical Practice: London, Pharmaceutical Press, 2003: pp. 178-183.
9. Lee T W, Robinson J., Controlled-release drug delivery systems. In: Remington: The Science and Practice of Pharmacy, 20th edition, Gennaro A R, Der Marderosian A H, Hanson G R, et al. (eds): Baltimore, MD, Lippincott Williams & Wilkins, 2000: pp. 917-918.
10. Kwangsukstith C, Maibach H I., Effect of age and sex on the induction and elicitation of allergic contact dermatitis. Contact Dermatitis 1995: 33: 289-298.